

# Overactivation of Oncogenic Signalling as a Potential Cancer Treatment Strategy Programme

Virtual Event

20 - 21 January 2026



## Scientific Programme

Tuesday 20th January 2026

**Listed times are in Central European Time (CET)**

- 12:00 **WELCOME TO DAY ONE**  
Chair: Rene Bernards
- 12:05 **Matheus Dias**  
NKI, Netherlands  
'Therapeutic OVERactivation of oncogenic signalling as a cancer treatment strategy'  
Q&A: 12:25-12:35
- 12:35 **Chrysa Papagianni**  
Netherlands Cancer Institute, Netherlands  
Proffered Paper 1: 'Overactivation of oncogenic signaling steers cancer cells towards less malignant phenotypes'  
Q&A: 12:45-12:50
- 12:50 **Dylan Farnsworth**  
BC Cancer Research Institute, Canada  
Proffered Paper 2: 'Disrupting proteostasis potentiates ERK hyperactivation in LUAD'  
Q&A: 13:00-13:05
- 13:05 **Vesselina Cooke**  
Novartis, USA  
'Small Molecule-induced ERK Hyperactivation as a Novel Therapeutic Approach for BRAF V600-Mutant Melanoma'  
Q&A: 13:25-13:35
- 13:35 **REFRESHMENT BREAK**  
Chair: Bart Vanhaesebroeck
- 13:50 **FLASH TALKS 1**  
A selection of high-scoring abstracts presented as 3 minute flash talks.
- 14:05 **Monica Roman-Trufero**  
Lausanne University Hospital, Switzerland  
Proffered Paper 3: 'GCN2 loss drives translational overdrive and metabolic collapse, creating a targetable cancer vulnerability'  
Q&A: 14:15-14:20
- 14:20 **Arun Unni**  
Weill Cornell Medicine, USA

'Understanding the consequences of excess RAS pathway activity in cancer cells'

Q&A: 14:40-14:50

14:50 REFRESHMENT BREAK

15:05 **Pia Giovannelli**

University of Campania Luigi Vanvitelli, Italy

Proffered Paper 4: 'Androgen Receptor Paradox: Overactivation of ERK Inhibits HRPC Growth'

Q&A: 15:15-15:20

15:20 **Marta Rubin**

University of Turin, Italy

Proffered Paper 5: 'Hyperactivation of ALK signaling triggered by PTPN2/PTPN1 pharmacologic inhibition induces oncogenic stress responses to promote tumor eradication in ALK-positive lymphoma'

Q&A: 15:30-15:35

15:35 CLOSING KEYNOTE

**Markus Müschen**

Yale School of Medicine, USA

'Hyperactivation of oncogenic STAT5-signaling as treatment strategy for tyrosine kinase-driven leukemia'

Q&A: 16:05-16:20

16:20 SUMMARY AND CLOSE

## Wednesday 21st January 2026

**Listed times are in Central European Time (CET)**

12:00 WELCOME TO DAY TWO

Chair: Bart Vanhaesebroeck

12:05 **Benoit Bilanges**

UCL Cancer Institute, UK

'Pharmacological activation of PI3K $\alpha$  triggers cancer cell death under metabolic stress'

Q&A: 12:25-12:35

12:35 **Marina Baessa**

IPATIMUP / i3s, Portugal

Proffered Paper 6: 'Therapeutic T-cell receptor activation in T-cell acute lymphoblastic leukemia'

Q&A: 12:45-12:50

12:50 **Eunice Cho**

The Broad Institute, USA

'Directed clonal evolution: Exploiting divergent MAPK inhibitor resistance for convergent hypersensitivity to MAPK hyperactivation'

Q&A: 13:10-13:20

13:20 REFRESHMENT BREAK

13:40 FLASH TALKS 2

A selection of high-scoring abstracts presented as 3 minute flash talks.

- 13:50 **David Santamaria**  
CIC (Cancer Research Center of Salamanca), Spain  
Proffered Paper 7: 'MAPK hyper-signalling driven by DUSP4 inactivation modulates the onset and progression of KRAS mutant lung adenocarcinoma'  
Q&A: 14:00-14:05
- 14:05 **Andrew Intlekofer**  
MSKCC, USA  
'Enzyme hyperactivation to target oncometabolism'  
Q&A: 14:25-14:35
- 14:35 **REFRESHMENT BREAK**  
Chair: Rene Bernards
- 14:50 **Ana Banito**  
German Cancer Research Center (DKFZ), Germany  
Proffered Paper 8: 'A dynamic balance between vPRC1 complexes finetunes oncogenesis activity in synovial sarcoma'  
Q&A: 15:00-15:05
- 15:05 **CLOSING KEYNOTE**  
**Kimberly Stegmaier**  
Dana-Farber Cancer Institute, USA  
'EWS::FLI1 Activation Lethality in Ewing Sarcoma'  
Q&A 15:35-15:50
- 15:50 **DISCUSSION SESSION**  
Will over activation cause cancer or cure cancer?
- 16:30 **CONFERENCE SUMMARY AND CLOSE**